Extended Use of Ivabradine in Heart Failure with Preserved Ejection Fraction and Inappropriate Sinus Tachycardia

Dr I SATHYAMURTHY, Dr KANTHALLU NARAYANAMOORTHY SRINIVASAN
{"title":"Extended Use of Ivabradine in Heart Failure with Preserved Ejection Fraction and Inappropriate Sinus Tachycardia","authors":"Dr I SATHYAMURTHY, Dr KANTHALLU NARAYANAMOORTHY SRINIVASAN","doi":"10.59793/ijcp.v34i9.779","DOIUrl":null,"url":null,"abstract":"Ivabradine has been used for over a decade in managing chronic coronary syndromes and heart failure (HF) with reducedejection fraction (HFrEF). HF with preserved ejection fraction (HFpEF) accounts for 50% of the total HF cases carrying equalmortality and morbidity risk as HFrEF. Increased heart rate (HR) in such cases has been shown to be associated with poorclinical outcomes. Clinical conditions like inappropriate sinus tachycardia (IST) manifest with elevated HR without anyspecific triggers. Beta-blockers have been the preferred treatment of choice for both HFpEF and IST but are often ineffective orpresent with side effects due to their negative ionotropic effects. Ivabradine, through its inhibitory action on funny current(Ifc), reduces HR without altering the inotropic mechanism. Few case reports and small case series have documented itsextended use and efficacy in reducing HR in these cardiac conditions. In this article, we present two cases who needed HRcontrol, one with HFpEF and another case of IST syndrome. Ivabradine was successfully used in both these cases to controlthe elevated HR.","PeriodicalId":506647,"journal":{"name":"Indian Journal Of Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal Of Clinical Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.59793/ijcp.v34i9.779","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Ivabradine has been used for over a decade in managing chronic coronary syndromes and heart failure (HF) with reducedejection fraction (HFrEF). HF with preserved ejection fraction (HFpEF) accounts for 50% of the total HF cases carrying equalmortality and morbidity risk as HFrEF. Increased heart rate (HR) in such cases has been shown to be associated with poorclinical outcomes. Clinical conditions like inappropriate sinus tachycardia (IST) manifest with elevated HR without anyspecific triggers. Beta-blockers have been the preferred treatment of choice for both HFpEF and IST but are often ineffective orpresent with side effects due to their negative ionotropic effects. Ivabradine, through its inhibitory action on funny current(Ifc), reduces HR without altering the inotropic mechanism. Few case reports and small case series have documented itsextended use and efficacy in reducing HR in these cardiac conditions. In this article, we present two cases who needed HRcontrol, one with HFpEF and another case of IST syndrome. Ivabradine was successfully used in both these cases to controlthe elevated HR.
伊伐布雷定在射血分数保留型心力衰竭和不适当窦性心动过速患者中的长期应用
伊伐布雷定用于治疗慢性冠状动脉综合征和射血分数降低的心力衰竭(HF)已有十多年的历史。射血分数保留型心力衰竭(HFpEF)占心力衰竭病例总数的 50%,其死亡率和发病风险与 HFrEF 相当。此类病例的心率(HR)增快已被证明与临床预后不良有关。不适当的窦性心动过速(IST)等临床症状表现为心率增快,但没有任何特定的诱因。β-受体阻滞剂一直是治疗高频心动过速和窦性心动过速的首选药物,但由于其负离子传导作用,往往效果不佳或存在副作用。伊伐布雷定通过抑制滑稽电流(Ifc),在不改变肌力机制的情况下降低心率。很少有病例报告和小型病例系列记录了伊伐布雷定在这些心脏疾病中的应用和降低心率的疗效。在本文中,我们介绍了两个需要控制心率的病例,其中一个患有 HFpEF,另一个患有 IST 综合征。伊伐布雷定在这两个病例中都成功地控制了心率升高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信